Navigation Links
Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
Date:3/25/2008

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced the initiation of a pivotal Phase 3 trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, in patients following bunionectomy surgery. The multicenter, double-blind, placebo-controlled trial will evaluate the efficacy and safety of Adlea in reducing post-surgical pain in patients undergoing a bunionectomy procedure. Adlea, which is designed to provide pain relief for weeks to months after a single local application, has already demonstrated statistically significant pain reduction in this clinical setting.

A bunionectomy is a surgical procedure that is performed to align the bones of the big toe joint by removing a bunion, which is an enlargement of the joint at the base of the big toe. An estimated 292,000 bunionectomy surgeries are performed in the U.S. each year.

"Because bunionectomies are often performed as out-patient procedures, patients are responsible for their own pain management following surgery. Adlea could fill an important need since it does not require repeated administrations after the initial application during surgery," said Dr. Eric L. Diamond, a podiatrist practicing in Maryland who is an investigator on the Phase 3 study and who also participated in a Phase 2 study of Adlea in bunionectomy surgery. "Furthermore, because Adlea is administered at the surgical site, its effects are targeted. In contrast to systemic pain medications such as opioids, Adlea appears to avoid potentially serious side effects on cognitive function and other organs or muscle groups. This profile affords it the potential to be safely used in conjunction with, and possibly reduce the need for, othe
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
2. Anesiva Defines Regulatory Pathway for Adlea with FDA
3. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
4. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
9. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
10. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
11. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... NORTHBROOK, Ill. , July 22, 2014 /PRNewswire/ ... has announced that the U.S. Food and Drug ... standards as consensus standards for medical devices incorporating ... UL 2054 - Standard for Household and Commercial ... Batteries (Cells). Consensus standards are ...
(Date:7/22/2014)... WASHINGTON, New York , July ... Neue Partnerschaft für umfassenden Schutz ... Medikamenteneinwirkungen in Österreich    ... Anbieter von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) ... Medikus , einen Vertriebshändler und Hersteller ...
(Date:7/21/2014)... July 21, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... results for the second quarter of fiscal year 2014 ... hold a conference call to discuss its financial results ... 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight ...
Breaking Medicine Technology:Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2Thoratec Schedules Second Quarter Conference Call, Webcast 2
(Date:7/22/2014)... The donation from the Edusei Foundation was ... In a feat of strategic engineering, such assistance tends to ... of the beneficiaries. It provided a sense of family to ... The Edusei Foundation donated various amounts of; milk, ... indomie. , The Government of Ghana established the Kumasi Children’s ...
(Date:7/22/2014)... New York (PRWEB) July 22, 2014 ... report published by Transparency Market Research “Circulating ... [Technologies: Tumor Cell Enrichment (Filtration, Centrifugation and ... Detection (Molecular Methods and Optical Methods) and ... and Others] - Global Industry Analysis, Size, ...
(Date:7/22/2014)... 22, 2014 Hospitals & ... was conducted by Hospitals & Health Networks ... AT&T, CareTech Solutions, The College of Healthcare ... Wired list recognizes hospitals for successful health ... hospitals in four focus areas: business and ...
(Date:7/22/2014)... July 22, 2014 Over the ... almost every sphere of human anatomy. In the ... advancements that rendered the possibility of deploying certain ... blood and tissues, in order to detect the ... abnormality. Essentially, In-vitro Diagnostics (IVD) have earned the ...
(Date:7/22/2014)... -- People who suffer long-term sleep problems after a ... pressure, a new study suggests. Previous research has ... death, but few studies have examined the reasons for ... causes, according to the University of Arizona investigators. ... or divorced for about 16 weeks. They reported on ...
Breaking Medicine News(10 mins):Health News:Edusei Foundation Donates Food and Needed Items to Kumasi Children’s Home in Ashanti Region of Ghana 2Health News:Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020 2Health News:Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020 3Health News:Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020 4Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 2Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 3Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 4Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2
... Oct. 6 The following is a,transcript of a ... THE PRESIDENT: Good morning., One important commitment of ... access to health care. Most of these children are,covered ... to help them,this fiscal year. For children who do ...
... 5 Marion Jones-Thompson, 31,of Austin, Texas, pleaded ... federal agencies in connection with two investigations,conducted out ... the Northern,District of California, respectively; Michael J. Garcia, ... New York; and Scott N. Schools, the,United States ...
... , Why: According to the Department of Defense, the signature ... in the conflicts in Iraq and Afghanistan ... survivors at risk of TBI. Government reports cite ... 5,500 service members with the potential ...
... Advance Heart Care Treatment, Physician Program at Montefiore Will, ... Satisfaction, NEW YORK, Oct. 5 Thousands of ... top quality, comprehensive,cardiac care in an innovative cardiovascular program ... receive incentive payments based on 60,performance measures for outpatient ...
... aspects to creating an effective drug: finding a chemical ... side-effects and then delivering it to the right place ... With the support from a $478,000, five-year CAREER award ... the second part of this problem. She is creating ...
... AUSTIN, Texas, Oct. 5 AARP today said a,proposed ... amounts,to one more backroom deal that ignores the interests ... new debt for a mere,one-time $15 electric bill credit. ... Jackson, AARP Texas,state director. "They,ll be the ones having ...
Cached Medicine News:Health News:Radio Address by President Bush to the Nation 2Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 2Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 3Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 4Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 5Health News:Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries 2Health News:Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries 3Health News:Novel Approach to Improving Cardiovascular Care 2Health News:Novel Approach to Improving Cardiovascular Care 3Health News:Novel Approach to Improving Cardiovascular Care 4Health News:Developing a modular, nanoparticle drug delivery system 2Health News:Developing a modular, nanoparticle drug delivery system 3Health News:AARP Calls on State Regulators to Reject Proposed Settlement of TXU Buyout 2
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Designated most popular model or size. 3 mm tip....
Medicine Products: